WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its proprietary antibody-drug conjugate
(ADC) technology, today announced that the following presentations by
Company management at upcoming investor conferences will be webcast:
-
Morgan Stanley Global Healthcare Conference
9:10 am ET,
September 11 in New York, NY
-
Stifel Nicolaus 2013 Healthcare Conference
11:30 am ET,
September 12 in Boston, MA
The webcasts will be accessible live through the "Investor Information"
section of the Company's website, www.immunogen.com;
a replay will be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
proprietary ADC technology uses a tumor-targeting engineered antibody to
deliver one of ImmunoGen's highly potent cancer-cell killing agents
specifically to tumor cells. The most advanced compound using
ImmunoGen's Targeted Antibody Payload (TAP) technology, Kadcyla®,
is marketed in the US by Genentech, a member of the Roche Group, and
undergoing regulatory review in the European Union and Japan. ImmunoGen
has four wholly owned clinical-stage compounds, with additional
compounds in the clinic through partnerships. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a trademark of Genentech.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media